Form 4: Geron Corp Executive James Ziegler Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
EVP and Chief Commercial Officer of Geron Corporation, James Ziegler, reports acquisition of stock options and restricted stock units.
Summary
- On February 18, 2025, James Ziegler, the EVP and Chief Commercial Officer of Geron Corporation, acquired stock options and restricted stock units (RSUs).
- Ziegler acquired options to purchase 529,000 shares of common stock at an exercise price of $2.63.
- These options vest in installments, beginning six months after his hire date of September 9, 2024, and continuing monthly thereafter.
- He also acquired 89,000 RSUs, each representing the right to receive one share of Geron's common stock.
- These RSUs vest in four equal annual installments from the grant date.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the executive and the company's future.
Positives
- The acquisition of stock options and RSUs suggests confidence in Geron's future performance by a key executive.
- The vesting schedules for both the options and RSUs incentivize long-term commitment from Mr. Ziegler.
Future Outlook
The vesting schedules of the stock options and RSUs suggest an expectation of continued service and contribution from the executive over the coming years.
Industry Context
Stock options and RSUs are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders and incentivize long-term value creation.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice in the biotech industry to attract and retain talent.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation strategies for their executives.
- The vesting schedules described are typical, with multi-year vesting periods to encourage long-term commitment.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term value creation.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 2024/09/09 | Reporting Person's date of hire |
| 2025/02/18 | Date of transaction (grant date for options and RSUs) |
| 2025/02/20 | Date of signature |
| 2035/02/17 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.